You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Mental health, behavioural and neurodevelopmental conditions
  5. Dementia

Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease

  • Technology appraisal guidance
  • Reference number: TA217
  • Published:  23 March 2011
  • Last updated:  20 June 2018
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

Research recommendations coming out of this guidance

  • Research is needed to generate robust and relevant data on the effects of treating people with Alzheimer’s disease on both short-term and long-term outcomes, disease progression through relevant health states, and quality of life.

  • Research is needed on the impact of treating Alzheimer’s disease on mortality and institutionalisation, and to assess the relationship between disease progression and carer utility (quality of life).

Back to top